{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T02:52:33Z","timestamp":1771901553589,"version":"3.50.1"},"reference-count":44,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,11,23]],"date-time":"2022-11-23T00:00:00Z","timestamp":1669161600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","valueinhealthjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Value in Health"],"published-print":{"date-parts":[[2023,4]]},"DOI":"10.1016\/j.jval.2022.11.002","type":"journal-article","created":{"date-parts":[[2022,11,11]],"date-time":"2022-11-11T10:09:00Z","timestamp":1668161340000},"page":"477-486","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Cost-Effectiveness of Venetoclax Plus Obinutuzumab Versus Chlorambucil Plus Obinutuzumab for the First-Line Treatment of Adult Patients With Chronic Lymphocytic Leukemia: An Extended Societal View"],"prefix":"10.1016","volume":"26","author":[{"given":"Ngoc","family":"Do","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0312-5891","authenticated-orcid":false,"given":"Frederick W.","family":"Thielen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.jval.2022.11.002_bib1","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.annonc.2020.09.019","article-title":"Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"32","author":"Eichhorst","year":"2021","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.jval.2022.11.002_bib2","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1007\/s40273-015-0332-5","article-title":"Cost effectiveness of ofatumumab plus chlorambucil in first-line chronic lymphocytic leukaemia in Canada","volume":"34","author":"Herring","year":"2016","journal-title":"Pharmacoeconomics"},{"issue":"42","key":"10.1016\/j.jval.2022.11.002_bib3","first-page":"2153","article-title":"Chronic lymphocytic leukemia (in German: chronische lymphatische Leuk\u00e4mie). Chronic lymphocytic leukemia","volume":"138","author":"Maurer","year":"2013","journal-title":"Dtsch Med Wochenschr"},{"issue":"9","key":"10.1016\/j.jval.2022.11.002_bib7","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1016\/S1470-2045(20)30443-5","article-title":"Venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (CLL14): follow-up results from a multicentre, open-label, randomised, phase 3 trial","volume":"21","author":"Al-Sawaf","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jval.2022.11.002_bib9","series-title":"Methods for the Economic Evaluation of Health Care Programmes","author":"Drummond","year":"2015"},{"key":"10.1016\/j.jval.2022.11.002_bib10","series-title":"Decision Modelling for Health Economic Evaluation","author":"Briggs","year":"2006"},{"issue":"suppl 1","key":"10.1016\/j.jval.2022.11.002_bib12","article-title":"Cost-effectiveness of a 12-month fixed duration of venetoclax in combination with obinutuzumab in first-line chronic lymphocytic leukemia in the United States","volume":"134","author":"Davids","year":"2019","journal-title":"Blood"},{"issue":"suppl 1","key":"10.1016\/j.jval.2022.11.002_bib13","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1182\/blood-2020-134596","article-title":"Cost-effectiveness of a 12-month fixed duration of venetoclax in combination with obinutuzumab versus chemoimmunotherapy and other novel combinations in first-line chronic lymphocytic leukemia in Canada","volume":"136","author":"Chatterjee","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.jval.2022.11.002_bib14","doi-asserted-by":"crossref","first-page":"S29","DOI":"10.1016\/j.jval.2021.04.149","article-title":"PCN57 cost-effectiveness of venetoclax in combination with obinutuzumab in first-line chronic lymphocytic leukemia in Colombia","volume":"24","author":"Ordo\u00f1ez","year":"2021","journal-title":"Value Health"},{"issue":"3","key":"10.1016\/j.jval.2022.11.002_bib16","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1111\/j.1365-2753.2008.01033.x","article-title":"Assessment of transparency of cost estimates in economic evaluations of patient safety programmes","volume":"15","author":"Fukuda","year":"2009","journal-title":"J\u00a0Eval Clin Pract"},{"issue":"11","key":"10.1016\/j.jval.2022.11.002_bib17","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1007\/s40273-019-00825-1","article-title":"The challenge of transparency and validation in health economic decision modelling: a view from Mount Hood","volume":"37","author":"Kent","year":"2019","journal-title":"Pharmacoeconomics"},{"issue":"10","key":"10.1016\/j.jval.2022.11.002_bib19","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1001\/jama.2016.12195","article-title":"Recommendations for conduct, methodological practices, and reporting of cost-effectiveness analyses: second panel on cost-effectiveness in health and medicine","volume":"316","author":"Sanders","year":"2016","journal-title":"JAMA"},{"key":"10.1016\/j.jval.2022.11.002_bib20","doi-asserted-by":"crossref","unstructured":"Allen C, Mehler DMA. Open science challenges, benefits and tips in early career and beyond [published correction appears in PLoS Biol. 2019;17(12):e3000587]. PLoS Biol. 2019;17(5):e3000246.","DOI":"10.1371\/journal.pbio.3000246"},{"issue":"4","key":"10.1016\/j.jval.2022.11.002_bib22","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1111\/j.1524-4733.2008.00489.x","article-title":"Transferability of economic evaluations across jurisdictions [ISPOR Good Research Practices Task Force report]","volume":"12","author":"Drummond","year":"2009","journal-title":"Value Health"},{"key":"10.1016\/j.jval.2022.11.002_bib23","series-title":"Evidence-Based Decisions and Economics","article-title":"Generalisability, transferability, complexity and relevance","author":"Walker","year":"2010"},{"issue":"1","key":"10.1016\/j.jval.2022.11.002_bib24","article-title":"The impact of patent expiry on drug prices: insights from the Dutch market","volume":"9","author":"van der Schans","year":"2020","journal-title":"J\u00a0Mark Access Health Policy"},{"key":"10.1016\/j.jval.2022.11.002_bib25","author":"Woods"},{"issue":"10","key":"10.1016\/j.jval.2022.11.002_bib26","first-page":"1176","article-title":"A\u00a0comparison of partitioned survival analysis and state transition multi-state modelling approaches using a case study in oncology","volume":"23","author":"Cranmer","year":"2020","journal-title":"J\u00a0Med Econ"},{"issue":"1","key":"10.1016\/j.jval.2022.11.002_bib27","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1186\/1471-2288-11-139","article-title":"Improved curve fits to summary survival data: application to economic evaluation of health technologies","volume":"11","author":"Hoyle","year":"2011","journal-title":"BMC Med Res Methodol"},{"issue":"11","key":"10.1016\/j.jval.2022.11.002_bib28","first-page":"1532","article-title":"Cost-effectiveness of a 12-month fixed-duration venetoclax treatment in combination with obinutuzumab in first-line, unfit chronic lymphocytic leukemia in the United States","volume":"27","author":"Chatterjee","year":"2021","journal-title":"J\u00a0Manag Care Spec Pharm"},{"key":"10.1016\/j.jval.2022.11.002_bib29","author":"Latimer"},{"issue":"6","key":"10.1016\/j.jval.2022.11.002_bib30","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1177\/0272989X12472398","article-title":"Survival analysis for economic evaluations alongside clinical trials--extrapolation with patient-level data: inconsistencies, limitations, and a practical guide","volume":"33","author":"Latimer","year":"2013","journal-title":"Med Decis Making"},{"key":"10.1016\/j.jval.2022.11.002_bib32","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.leukres.2016.09.005","article-title":"Cost-effectiveness of obinutuzumab for chronic lymphocytic leukaemia in the Netherlands","volume":"50","author":"Blommestein","year":"2016","journal-title":"Leuk Res"},{"issue":"1","key":"10.1016\/j.jval.2022.11.002_bib33","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.leukres.2013.10.029","article-title":"Real-world costs of chronic lymphocytic leukaemia in the Netherlands","volume":"38","author":"Holtzer-Goor","year":"2014","journal-title":"Leuk Res"},{"key":"10.1016\/j.jval.2022.11.002_bib34","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/1477-7525-8-50","article-title":"Population preference values for treatment outcomes in chronic lymphocytic leukaemia: a cross-sectional utility study","volume":"8","author":"Beusterien","year":"2010","journal-title":"Health Qual Life Outcomes"},{"issue":"5","key":"10.1016\/j.jval.2022.11.002_bib35","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1007\/s10198-012-0419-2","article-title":"Utility elicitation study in the UK general public for late-stage chronic lymphocytic leukaemia","volume":"14","author":"Tolley","year":"2013","journal-title":"Eur J Health Econ"},{"issue":"2","key":"10.1016\/j.jval.2022.11.002_bib36","first-page":"164","article-title":"Costs of haematological adverse events in chronic myeloid leukaemia patients: a retrospective cost analysis of the treatment of anaemia, neutropenia and thrombocytopenia in patients with chronic myeloid leukaemia","volume":"12","author":"Bouwmans","year":"2009","journal-title":"J\u00a0Med Econ"},{"issue":"28","key":"10.1016\/j.jval.2022.11.002_bib37","doi-asserted-by":"crossref","first-page":"3193","DOI":"10.1016\/j.vaccine.2015.05.001","article-title":"Incidence, direct costs and duration of hospitalization of patients hospitalized with community acquired pneumonia: a nationwide retrospective claims database analysis","volume":"33","author":"Rozenbaum","year":"2015","journal-title":"Vaccine"},{"issue":"4","key":"10.1016\/j.jval.2022.11.002_bib38","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1016\/j.clinthera.2016.02.005","article-title":"Cost-effectiveness of first-line chronic lymphocytic leukemia treatments when full-dose fludarabine is unsuitable","volume":"38","author":"Soini","year":"2016","journal-title":"Clin Ther"},{"issue":"3","key":"10.1016\/j.jval.2022.11.002_bib39","doi-asserted-by":"crossref","first-page":"175","DOI":"10.2165\/11586130-000000000-00000","article-title":"Standardizing the inclusion of indirect medical costs in economic evaluations","volume":"29","author":"van Baal","year":"2011","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.jval.2022.11.002_bib41","doi-asserted-by":"crossref","first-page":"2225","DOI":"10.1056\/NEJMoa1815281","article-title":"Protocol: venetoclax and obinutuzumab in patients with CLL and coexisting conditions","volume":"380","author":"Fischer","year":"2019","journal-title":"N\u00a0Engl J Med"},{"issue":"17","key":"10.1016\/j.jval.2022.11.002_bib43","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1182\/blood.2020004922","article-title":"Cost-effectiveness of first-line vs third-line ibrutinib in patients with untreated chronic lymphocytic leukemia","volume":"136","author":"Patel","year":"2020","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.jval.2022.11.002_bib44","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1159\/000496834","article-title":"What does the pipeline promise about upcoming biosimilar antibodies in oncology?","volume":"14","author":"Busse","year":"2019","journal-title":"Breast Care (Basel)"},{"issue":"8","key":"10.1016\/j.jval.2022.11.002_bib45","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1097\/CAD.0000000000000648","article-title":"Potential cost savings owing to the route of administration of oncology drugs: a microcosting study of intravenous and subcutaneous administration of trastuzumab and rituximab in the Netherlands","volume":"29","author":"Franken","year":"2018","journal-title":"Anti Cancer Drugs"},{"issue":"suppl 1","key":"10.1016\/j.jval.2022.11.002_bib46","article-title":"Prevention and management of tumor lysis syndrome in patients with CLL and coexisting conditions treated with venetoclax-obinutuzumab or chlorambucil-obinutuzumab: results from the randomized CLL14 trial","volume":"134","author":"Al-Sawaf","year":"2019","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.jval.2022.11.002_bib47","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.clml.2017.09.015","article-title":"Clinical practice guidelines for diagnosis and treatment of chronic lymphocytic leukemia (CLL) in the Netherlands","volume":"18","author":"Kersting","year":"2018","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"11","key":"10.1016\/j.jval.2022.11.002_bib48","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0187477","article-title":"Update of the Dutch manual for costing studies in health care","volume":"12","author":"Kanters","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.jval.2022.11.002_bib49","author":"Hakkaart-van Roijen"},{"issue":"10","key":"10.1016\/j.jval.2022.11.002_bib54","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1016\/j.jval.2019.05.004","article-title":"A\u00a0value of information analysis of research on the 21-gene assay for breast cancer management","volume":"22","author":"Kunst","year":"2019","journal-title":"Value Health"},{"issue":"3","key":"10.1016\/j.jval.2022.11.002_bib56","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1177\/0272989X13505910","article-title":"Estimating multiparameter partial expected\u00a0value of perfect information from a probabilistic sensitivity analysis sample:\u00a0a nonparametric regression approach","volume":"34","author":"Strong","year":"2014","journal-title":"Med Decis Mak"},{"issue":"3","key":"10.1016\/j.jval.2022.11.002_bib60","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1177\/0272989X15586552","article-title":"Interpretation of the expected value of perfect information and research recommendations: A systematic review and empirical investigation","volume":"36","author":"Thorn","year":"2016","journal-title":"Med Decis Mak"},{"issue":"1","key":"10.1016\/j.jval.2022.11.002_bib62","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1186\/s13643-019-1188-0","article-title":"How should systematic reviewers handle conference abstracts? A view from the trenches","volume":"8","author":"Scherer","year":"2019","journal-title":"Syst Rev"},{"issue":"2","key":"10.1016\/j.jval.2022.11.002_bib63","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1007\/s40273-018-0749-8","article-title":"Future costs in cost-effectiveness analyses: past, present, future","volume":"37","author":"de Vries","year":"2019","journal-title":"Pharmacoeconomics"},{"issue":"8","key":"10.1016\/j.jval.2022.11.002_bib64","doi-asserted-by":"crossref","first-page":"609","DOI":"10.2165\/11537580-000000000-00000","article-title":"Time for cooperation in health economics among the modelling community","volume":"28","author":"Arnold","year":"2010","journal-title":"Pharmacoeconomics"}],"container-title":["Value in Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1098301522047325?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1098301522047325?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T01:31:10Z","timestamp":1761096670000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1098301522047325"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4]]},"references-count":44,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,4]]}},"alternative-id":["S1098301522047325"],"URL":"https:\/\/doi.org\/10.1016\/j.jval.2022.11.002","relation":{},"ISSN":["1098-3015"],"issn-type":[{"value":"1098-3015","type":"print"}],"subject":[],"published":{"date-parts":[[2023,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cost-Effectiveness of Venetoclax Plus Obinutuzumab Versus Chlorambucil Plus Obinutuzumab for the First-Line Treatment of Adult Patients With Chronic Lymphocytic Leukemia: An Extended Societal View","name":"articletitle","label":"Article Title"},{"value":"Value in Health","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jval.2022.11.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 International Society for Pharmacoeconomics and Outcomes Research, Inc. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}